Skip to content
lifestyle.claritypointe.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Beam Therapeutics
BEAM-302 Data for AATD: Promising Results at ERS Congress
September 8, 2026
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
September 1, 2026
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
August 4, 2026
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
May 24, 2026
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 23, 2026
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
May 22, 2026
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 21, 2026
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
March 25, 2026